Good afternoon, and welcome to scPharmaceuticals fourth-quarter and full-year 2024 earnings conference call. (Operator Instructions) As a reminder, today's conference is being recorded. I would now ...

Maxim analyst Naz Rahman lowered the firm’s price target on scPharmaceuticals (SCPH) to $12 from $20 but keeps a Buy rating on the shares after ...

Discover scPharmaceuticals' Q4 2024 achievements, including FUROSCIX's CKD approval, Medicare redesign insights, and strategies for 2025 growth.

Pharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S ...

Reports Q4 revenue $12.2M, consensus $12.18M..Reports Net FUROSCIX revenue of $12.2m and $36.3mfor the fourth quarter and full year 2024, ...

Furoscix is a pH-neutral formulation of furosemide, a loop diuretic, designed for subcutaneous (SC) administration via a wearable, single-use, pre-programmed on-body infusor for outpatient ...

(Politico) The FDA expanded the approval of furosemide (Furoscix) to include treatment of edema in adults with chronic kidney ...

Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...

Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure.

Cardiorenal specialist scPharmaceuticals has won US Food and Drug Administration (FDA) approval for its supplemental New Drug Application (sNDA) for Furoscix (furosemide injection) to expand the ...

(RTTNews) - scPharmaceuticals Inc. (SCPH) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for FUROSCIX to expand the indication ...

Get Our Latest Report on scPharmaceuticals scPharmaceuticals Stock Down 1.9 % Shares of NASDAQ:SCPH opened at $3.12 on Wednesday. The firm has a market capitalization of $156.12 million, a PE ...